INTRODUCTION S
TEM CELLS have emerged from condign obscurity to remarkable levels of prominence in both the scientific literature and lay consciousness. Reports in peer-reviewed journals are carried as front page news in the New York Times and are summarized on nightly national network news. Time, Newsweek, Business Week, The Atlantic Monthly, and many of their peer journals have all carried in-depth cover stories on stem cells. C-Span broadcast the full two-day National Academy of Sciences Workshop on the topic. Stem cells can fairly be said to have provided many scientists with their "fifteen minutes of fame."
Why all the attention, all of a sudden? First, of course, was Dolly and the paradigmatic revelation that a fully differentiated adult cell could be reprogrammed back to totipotent stem cell status. 1 So far, at least, the technologies for cloning and stem cell biology are inseparable: it is not yet possible to create a clone without first creating a stem cell by nuclear transfer. Furthermore, advances in the understanding of basic stem cell biology have potential relevance to therapeutic or reproductive cloning. Not long after Wilmut's announcement of Dolly came the techniques for isolating and culturing human embryonic stem cells as well as the capability to begin teasing the cultured cells down defined lineage pathways. 2, 3 Working largely with murine models, other investigators demonstrated that embryonic stem cells could be converted into tissue with functional utility in animal models of diabetes and Parkinson's disease. 4, 5 Other investigators pursued adult stem cells, discovering a hitherto unsuspected capacity for transdifferentiation. [6] [7] [8] However, the plasticity of adult stem cells has become a controversial issue due to problems of separation, identification, proliferation, and cell fusion. Another controversial but certainly attention-getting issue arose with the reports of the cloning of an early stage human embryo by nuclear transfer 9 and the claim that parthenogenesis may eventually compete with nuclear transfer as a technique for cloning adult mammals. 10 This dramatic progress was well summarized in an editorial in Nature last November by N. DeWitt 11 : "Stem cells are truly remarkable. They bridge the gulf between the fertilized egg that is our origin and the architecture that we become. They supply the cells that construct our bodies and, as we age, replenish worn out, damaged, and diseased tissues. They renew themselves, resisting the powerful pull toward diferentiation that overcomes more prosaic cells. 
METHODS
To be eligible for inclusion in this study, firms needed to be significantly vested in stem cell technology. Typical focus areas included embryonic or adult stem cells, nuclear transfer and therapeutic cloning, banking or cord blood, and development or sale of enabling equipment and supplies. All firms identified by the NIH as custodians of "approved" stem cell lines were included. Not-for-LYSAGHT AND HAZLEHURST profit organizations were excluded, as were firms involved in reproductive cloning of pets and livestock animals. Conventional bone marrow transplantation did not qualify. Firms that were peripherally or incidentally involved in stem cells were not included.
A list of qualifying firms was compiled from general awareness of the field, from keyword Web searches, from companies whose scientists presented at relevant technical or investor conferences (Pittsburgh Tissue Engineering Initiative, Society for Regenerative Medicine, Techvest), and from the trade literature. 12 Once compiled, the list was circulated to and vetted by individuals knowledgeable in the field. The compilation is believed to be reasonably complete, although some smaller and newer firms will inevitably be missed in a field growing as rapidly as this.
A profile on each firm was then developed, including principal technical focus, date of founding, number of employees, source of funding, and, where appropriate, the fraction of the firm's efforts that was dedicated to stem cells. For public firms, this information was available from annual reports and SEC filings. For private firms, the information was obtained from the firm's Web site or by contacting the CEO (chief executive officer) or CFO (chief financial officer). Firms conducting operations in more than one country were asked for a breakdown of employees by geographic region. In a few cases, only a range of the number of full time equivalents (FTEs) was available; here, the midvalue of the range is reported. Wherever possible, information was doublechecked against information available from proprietary databases. 13 Private firms were generally unwilling to disclose their annual spending rate. Accordingly, where not directly available, this number was estimated from a lumped sum correlation of $200,000 in total annual company expenditure per employee per year. This correlation had been validated in earlier surveys of the tissue-engineering field. 14, 15 Capital value for public companies was calculated as the product of the number of shares times individual share value, as of June 30, 2002. Number of shares was obtained from company financial statements and share values from on-line listings. Share values denominated in foreign currencies were converted to dollars at the exchange rates prevailing on June 30, 2002. For firms involved in activities other than stem cells, the capital value was prorated according to the fraction of the firm's activity devoted to stem cells. This implicitly assumes that all of a firm's activities contribute equally to its capital value.
556
One firm in the survey, PPL Ltd., announced in April of 2002 its intention to sell or spin off its stem cell activities. Since the announced intention was to divest, rather than discontinue, operations and since the restructuring had not yet taken place, PPL"s stem cell activities are included in this report under PPL's name.
RESULTS
As of mid-2002, private sector research and development in stem cells is being conducted by ,1000 scientists and support staff in 33 firms, operating in 11 countries. Aggregate spending is $208 million. Six of the 33 firms are public; the remaining are private. Capital value of the public companies, prorated for their involvement in stem cells, is $180 million, although the largest firm is responsible for well over half this total.
The Appendix lists the firms, gives their locations and Web sites, lists the number of employees, and provides a thumbnail sketch of each firm's activities. Figure 1 contains piecharts illustrating the proportion of firms in different stem cell activities, the fractions working on adult versus embryonic stem cells, and the geographical distribution of firms and employees. Table 2 lists the firms serving as repositories for "approved" human stem cell lines, ie those which can be used in federally funded US research. Table 3 summarizes the total and prorated capital value, as of the close of the second quarter of 2002, for those firms that are publicly traded.
PRIVATE SECTOR DEVELOPMENT

DISCUSSION
Approximately 1000 FTEs and their associated costs is a substantial commitment but the net involvement of the private sector is nevertheless quite modest. Aggregate stem cell activity in the private sector is six times smaller than the total funds devoted each year to tissueengineering research and development. It is approximately the size of the staff that a pharmaceutical company would deploy for a single drug for each of the dozen years required to bring a lead compound to markets. And it represents less than 1.5% of the annual research budget of Pfizer, a single drug company.
The size distribution of the individual firms is also telling. Companies with fewer than 15 employees (a broad plurality of stem cell companies) are really just getting started. By the time a firm has 15-35 employees it can conduct discovery-level science and highly productive firms of this size can certainly impact a field and create increments in shareholder value through intellectual property. However, the actual discovery, definition, development, and regulatory management of a product are extremely labor intensive. It would be highly unusual for a company to be successful at these latter activities with fewer than 100-150 employees.
Given their size and resources, what most stem cell firms are doing is developing technologies rather than products. The rationale is that such technologies will have realizable value as the field grows and matures. Companies are also investing in "squatter sovereignty" with the intention of developing infrastructure, experience, and trade skills that will allow them to participate in or even dominate a potentially explosive area of future biomedicine. Although high risk, these business models appear sound. In the absence of defined products a "small is beautiful" approach to stem cell startups may be appropriate.
LYSAGHT AND HAZLEHURST A few firms, for example, Osiris, do have defined products, and others are selling services such as neonatal stem cell banking, while still others make and sell the specialized equipment needed for nuclear transfer. But these are exceptions; most activity is centered in pure-play technology development firms.
Most of the startups are private and thus funded by capital from angels, venture groups, and mezzanine financiers. Six are public: three raised their funds as stem cell firms (Bresagen, Geron, and Renouron) and three (Curis, PPL, and Stem Cell, Inc.) raised funds under a different persona and subsequently moved their activities wholly or partially into stem cells. Given the current condition of the stock market, not very much can be read into the current capital value of public stem cell companies. The soundest conclusion is that the market appears to be lumping these companies together with other biotech startups, and that stem cell firms trade neither at a premium or discount over other early-stage biotech startups. The constant calliope of publicity about stem cells has not led to a rash of IPOs . . . which is probably a good thing. More disturbing is the lack of corporate partnerships or other flow of resources from large established pharmaceutical or medical device companies into stem cells. This source of revenue has been critical to the success of biotechnology in the past and will likely prove necessary for stem cells in the future.
Stem cell firms are highly diversified in both their technology approaches and geographical bases. The split of focus between adult cells and embryonic cells is about equal, at least in the number of firms working on each (see Fig. 1 ). This would seem to refute the common wisdom that embryonic stem cells are not "investable," although only time will tell if early investment is sustainable. The broad geographic base is also noteworthy. Some countries are distinctly more hospitable to embryonic stem cells and therapeutic cloning than others. Among countries that have established policies, the United Kingdom, Sweden, Israel, and Japan are the most permissive, while Germany and the United States are the 558 most constraining. Capital and scientists are likely to gravitate toward the region or environment where they can best flourish. Hence, the existence of a geographically dispersed industry ensures that restrictive legislation in one region will not stop the science from advancing. The private sector is just one of many sources of stem cell research and development. Government agencies both perform work in their own laboratories and fund research in universities and research institutes. Quasi-public and not-for-profit laboratories also support stem cell research. No total of public sector spending on stem cells seems to be available. Based on the number and impact of publications in the peer-reviewed literature, it would appear that publicly supported stem cell research equals or exceeds that of the private sector. This pattern differs from that in other areas of tissue engineering, where support has always come almost entirely from the private sector. Since the public and private sectors have different goals, different priorities, different time frames, and different constraints, a balance between the two seems very sensible. Genomics research is a good example of how a combination of critical mass research in both sectors can accelerate development in a field.
Private sector activity in stem cells has emerged as a small, clearly identifiable high tech cottage industry. If the past history of biotech startups is a guide, these firms are attended by zeal, focus, high energy, excitement, and enthusiasm. Their relatively small size is likely an advantage at the current stage of development. If, and when, the field of stem cell research achieves a clinically important role in 21st century healthcare, the commitment and belief of these early pioneers may indeed be amply rewarded.
